GlaxoSmithKline will pour $67 million into a new laboratory at the University of California to industrialize the search for drug clues using the gene-editing tool CRISPR.
Looking at gene function: CRISPR, you’ve heard by now, is the name for a type of molecular scissors that slices and edits DNA. The tool has led to a procession of gene-modified plants, animals, even human babies. Now Glaxo is spending money on a different use of CRISPR that’s less talked about, but maybe more important. The idea is to use it on cells growing in the lab, tweaking all 20,000 or so human genes (alone and in every possible combination) and watching what happens with tools that let scientists peer into individual cells. Are there special combinations that kill cancer? Any that explain why some people don’t get ill, despite a serious gene defect?
The center intends to carry these novel CRISPR screens forward to an industrial scale. Hal Barron, chief scientist at Glaxo, says a single experiment can generate 400 million data points. Machine-learning software will be needed to make sense of the information, and so will clues from large biobanks containing people’s health records.
Who is in charge?: That could become a prickly question. The new center has the backing of CRISPR experts Jennifer Doudna of UC Berkeley and Jonathan Weissman of UC San Francisco, with 24 university employees and 14 from the company. But Glaxo will pay the tab, so it will have a say in what research is done and the option to license patents on discoveries or new technologies.
Glaxo called the deal structure unique. In reality, though, drug industry efforts to get academia to perform its R&D are commonplace and sometimes problematic. A similar deal in 1998 between Berkeley and Novartis caused an uproar. The University of California campuses did not provide a copy of their contract with Glaxo.
“This will be fascinating to watch,” says Bob Berring, an emeritus professor of law at Berkeley. He points out that the deal was inked amid budget problems for the university and following a dispute over CRISPR patents between Berkeley and MIT. “The idea will be to make beaucoup dollars,” says Berring. “There will be questions about the impact that something like this has on questions like faculty equity and the direction of research."
Sam Altman invested $180 million into a company trying to delay death
Can anti-aging breakthroughs add 10 healthy years to the human life span? The CEO of OpenAI is paying to find out.
Forget designer babies. Here’s how CRISPR is really changing lives
The gene-editing tool is being tested in people, and the first treatment could be approved this year.
Neuroscientists listened in on people’s brains for a week. They found order and chaos.
The study shows that our brains exist between chaos and stability—a finding that could be used to help tweak them either way.
More than 200 people have been treated with experimental CRISPR therapies
But at a global genome-editing summit, exciting trial results were tempered by safety and ethical concerns.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.